On Monday, publicly-traded psychedelic company Cybin announced an overnight public offering, and its stock paid the price. This came as no surprise to...
Cybin has announced a public offering for gross proceeds of US$8,250,000. The post Raising Capital: Cybin Announces Public Offering appeared first on ...
The losses primarily stem from a surge in research and development costs. The post Psyence Group Reports $6M Loss Amid Expansion, Clinical Trials appeared...
The company saw an 11% rise in client appointments during the quarter, signaling headway. The post Clinic Appointments Give Numinus Rosy Outlook on Expansion...
Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, is pleased to announce an...
Source: Patrick Trucchio 07/19/2023 The firm continues advancing its lead drug candidates, including those for anxiety and treatment-resistant...
Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical‐stage natural psychedelic drug development company, today announced that it intends...
Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical‐stage natural psychedelic drug development company, and Jupiter Acquisition...
The agreement would merge Filament with Jupiter Acquisition Corporation (NASDAQ: JAQC) The post Filament Health Heading to NASDAQ With SPAC Merger appeared...
This story was reprinted with permission from Crain New York and written by Amanda D’Ambrosio. Last month, federal regulators released research guidance...